Adalta Limited (ASX:1AD)


right-arrow Created with Sketch. -0.003 (-3.61%)
MCAP $20.38M
Last trade 15.58pm 06/12/2021 20mins delayed

Latest Announcements

03/12/20211ADAdalta Limited
03/12/20211ADAdalta Limited
29/11/20211ADAdalta Limited
29/11/2021 Price SensitivePS1ADAdalta Limited
19/11/20211ADAdalta Limited
19/11/20211ADAdalta Limited
18/11/2021 Price SensitivePS1ADAdalta Limited
17/11/20211ADAdalta Limited

Company Overview

AdAlta Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on using its technology platform to generate protein therapeutics, known as i-bodies, for treating a range of human diseases. The Company’s lead candidate AD-214 is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases. AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules at the front end, that bind with high affinity to the human target. The i-body has also demonstrated its usefulness in treating fibrosis of the eye and is being pursued as an additional opportunity for the treatment of age-related macular degeneration (wet-AMD). The i-body is identified to have affinity and specificity with a drug target of interest, its effectiveness is evaluated in cell-based assays (in vitro) and in animal experiments (in vivo).

1AD in the news

AdAlta (1AD) is set to pocket a $4 million low-interest loan from…
AdAlta (AD1) teams up with Carina Biotech to combine their treatments to…
AdAlta (1AD) executes a non-dilutive funding agreement with Radium Capital to help…
AdAlta (1AD) has been granted a patent for its lead program AD-214…

Search Previous Announcements